This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moon, R. C. Articles by Sporn, M. B. Search for Related Content PubMed PubMed Citation Articles by Moon, R. C. Articles by Sporn, M. B.

N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat

IIT Research Institute, Chicago, Illinois 60616 [R. C. M., H. J. T., P. J. B., C. J. G.]; Johnson & Johnson, New Brunswick, New Jersey 08903 [R. J. G.]; and National Cancer Institute, Bethesda, Maryland 20014 [D. L. N., J. M. S., S. L. P., W. R. H., L. T. M., C. C. B., M. B. S.]

The synthesis of a new retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide, which has useful biological properties, is described. This retinoid was more potent than retinyl acetate in reversing keratinization caused by retinoid deficiency in tracheal organ culture. It was markedly less toxic than retinyl acetate when fed p.o. to rats over 2-week of 6-month periods. It was an effective agent for inhibition of the development of breast cancer induced in rats by N-nitroso-N-methylurea, although it was not as potent as retinyl acetate in this regard. However, the lesser toxicity of 4-hydroxyphenylretinamide makes it a superior agent for prevention of breast cancer. High-pressure liquid chromatographic analyses of liver and breast extracts from rats treated for 6 months with retinoids show the pharmacokinetic basis for the superiority of 4-hydroxyphenylretinamide; this retinoid and its metabolites were found in high concentrations in breast tissue, without any measurable accumulation in the liver or evident liver toxicity. In contrast, chronic feeding of retinyl acetate caused marked deposition of retinyl esters in the liver and severe hepatotoxicity. Whole mounts of rat mammary glands, made after chronic feeding of 4-hydroxyphenylretinamide, showed that it had a marked antiproliferative effect on mammary epithelium.

¹ To whom requests for reprints should be addressed.

Received 11/ 1/78. Accepted 1/12/79.

This article has been cited by other articles:

				H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan Involvement of Rac in Fenretinide-Induced Apoptosis Cancer Res., June 1, 2008; 68(11): 4416 - 4423. [Abstract] [Full Text] [PDF]

				A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes GADD153 (CHOP) and Bcl-2-Binding Component 3 (PUMA) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor Cancer Res., July 1, 2007; 67(13): 6270 - 6277. [Abstract] [Full Text] [PDF]

				S. M. McDaniel, C. O'Neill, R. P. Metz, E. Tarbutton, M. Stacewicz-Sapuntzakis, J. Heimendinger, P. Wolfe, H. Thompson, and P. Schedin Whole-Food Sources of Vitamin A More Effectively Inhibit Female Rat Sexual Maturation, Mammary Gland Development, and Mammary Carcinogenesis than Retinyl Palmitate J. Nutr., June 1, 2007; 137(6): 1415 - 1422. [Abstract] [Full Text] [PDF]

				K. Liby, M. Rendi, N. Suh, D. B. Royce, R. Risingsong, C. R. Williams, W. Lamph, F. Labrie, S. Krajewski, X. Xu, et al. The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5902 - 5909. [Abstract] [Full Text] [PDF]

				U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann. Onc., July 1, 2006; 17(7): 1065 - 1071. [Abstract] [Full Text] [PDF]

				S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF]

				S. Shishodia, A. M. Gutierrez, R. Lotan, and B. B. Aggarwal N-(4-Hydroxyphenyl)Retinamide Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis through Down-regulation of I{kappa}B{alpha} Kinase and Nuclear Factor-{kappa}B-Regulated Gene Products Cancer Res., October 15, 2005; 65(20): 9555 - 9565. [Abstract] [Full Text] [PDF]

				N. Ferrari, U. Pfeffer, R. Dell'Eva, C. Ambrosini, D. M. Noonan, and A. Albini The Transforming Growth Factor-{beta} Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide Clin. Cancer Res., June 15, 2005; 11(12): 4610 - 4619. [Abstract] [Full Text] [PDF]

				A.-M. Simeone, C.-X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells Carcinogenesis, May 1, 2005; 26(5): 1000 - 1007. [Abstract] [Full Text] [PDF]

				H. Kim, P. Hall, M. Smith, M. Kirk, J. K. Prasain, S. Barnes, and C. Grubbs Chemoprevention by Grape Seed Extract and Genistein in Carcinogen-induced Mammary Cancer in Rats Is Diet Dependent J. Nutr., December 1, 2004; 134(12): 3445S - 3452S. [Abstract] [Full Text] [PDF]

				N. Ferrari, M. Morini, U. Pfeffer, S. Minghelli, D. M. Noonan, and A. Albini Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide Clin. Cancer Res., December 1, 2003; 9(16): 6020 - 6029. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, M. R. Modiano, J. J. Lee, Y.-M. Peng, M.-J. Xu, H. Villar, W. S. Dalton, and S. M. Lippman Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide Clin. Cancer Res., July 1, 2003; 9(7): 2400 - 2405. [Abstract] [Full Text] [PDF]

				C. Zou, A.-T. Vlastos, L. Yang, J. Wang, M. Brewer, and M. Follen Effect of 4-Hydroxyphenylretinamide on Human Cervical Epithelial and Cancer Cell Lines Reproductive Sciences, January 1, 2003; 10(1): 41 - 48. [Abstract] [PDF]

				A.-M. Simeone, S. Ekmekcioglu, L. D. Broemeling, E. A. Grimm, and A. M. Tari A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide Mol. Cancer Ther., October 1, 2002; 1(12): 1009 - 1017. [Abstract] [Full Text] [PDF]

				S. E. Singletary, E. N. Atkinson, A. Hoque, N. Sneige, A. A. Sahin, H. A. Fritsche Jr., R. Lotan, T. Lu, W. N. Hittelman, T. B. Bevers, et al. Phase II Clinical Trial of N-(4-Hydroxyphenyl)retinamide and Tamoxifen Administration before Definitive Surgery for Breast Neoplasia Clin. Cancer Res., September 1, 2002; 8(9): 2835 - 2842. [Abstract] [Full Text] [PDF]

				F. Formelli Correspondence re: M. Follen et al., A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix. Clin. Cancer Res., 7: 3356-3365, 2001 Clin. Cancer Res., May 1, 2002; 8(5): 1310 - 1312. [Full Text] [PDF]

				K.-R. You, J. Wen, S.-T. Lee, and D.-G. Kim Cytochrome c Oxidase Subunit III. A MOLECULAR MARKER FOR N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED OXIDATIVE STRESS IN HEPATOMA CELLS J. Biol. Chem., February 1, 2002; 277(6): 3870 - 3877. [Abstract] [Full Text] [PDF]

				M. Follen, E. N. Atkinson, D. Schottenfeld, A. Malpica, L. West, S. Lippman, C. Zou, W. N. Hittelman, R. Lotan, and W. K. Hong A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., November 1, 2001; 7(11): 3356 - 3365. [Abstract] [Full Text] [PDF]

				T. Camerini, L. Mariani, G. De Palo, E. Marubini, M. G. Di Mauro, A. Decensi, A. Costa, and U. Veronesi Safety of the Synthetic Retinoid Fenretinide: Long-Term Results From a Controlled Clinical Trial for the Prevention of Contralateral Breast Cancer J. Clin. Oncol., March 15, 2001; 19(6): 1664 - 1670. [Abstract] [Full Text] [PDF]

				E. Singletary, R. Lieberman, N. Atkinson, N. Sneige, A. Sahin, S. Tolley, M. Colchin, T. Bevers, C. Stelling, B. Fornage, et al. Novel Translational Model for Breast Cancer Chemoprevention Study: Accrual to a Presurgical Intervention with Tamoxifen and N-[4-Hydroxyphenyl] Retinamide Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1087 - 1090. [Abstract] [Full Text]

				L. A. Hansen, C. C. Sigman, F. Andreola, S. A. Ross, G. J. Kelloff, and L. M. De Luca Retinoids in chemoprevention and differentiation therapy Carcinogenesis, July 1, 2000; 21(7): 1271 - 1279. [Abstract] [Full Text] [PDF]

				M. B. Sporn and N. Suh Chemoprevention of cancer Carcinogenesis, March 1, 2000; 21(3): 525 - 530. [Abstract] [Full Text] [PDF]

				A. Shilkaitis, A. Green, V. Steele, R. Lubet, G. Kelloff, and K. Christov Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death Carcinogenesis, February 1, 2000; 21(2): 227 - 233. [Abstract] [Full Text] [PDF]

				B. Conley, J. O’Shaughnessy, S. Prindiville, J. Lawrence, C. Chow, E. Jones, M. J. Merino, M. I. Kaiser-Kupfer, R. C. Caruso, M. Podgor, et al. Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer J. Clin. Oncol., January 14, 2000; 18(2): 275 - 275. [Abstract] [Full Text] [PDF]

				K. C. Lewis and J. F. Hochadel Retinoid Metabolism in the Prostate: Effects of Administration of the Synthetic Retinoid N-(4-Hydroxyphenyl)retinamide Cancer Res., December 1, 1999; 59(23): 5947 - 5955. [Abstract] [Full Text] [PDF]

				U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, et al. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1847 - 1856. [Abstract] [Full Text] [PDF]

				A. Green, A. Shilkaitis, and K. Christov 4-(Hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland Carcinogenesis, August 1, 1999; 20(8): 1535 - 1540. [Abstract] [Full Text] [PDF]

				Y. Chen, J. Buck, and F. Derguini Anhydroretinol Induces Oxidative Stress and Cell Death Cancer Res., August 1, 1999; 59(16): 3985 - 3990. [Abstract] [Full Text] [PDF]

				V. K. Puduvalli, Y. Saito, R. Xu, G. P. Kouraklis, V. A. Levin, and A. P. Kyritsis Fenretinide Activates Caspases and Induces Apoptosis in Gliomas Clin. Cancer Res., August 1, 1999; 5(8): 2230 - 2235. [Abstract] [Full Text] [PDF]

				A. Bednarek, A. Shilkaitis, A. Green, R. Lubet, G. Kelloff, K. Christov, and C. M. Aldaz Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors Carcinogenesis, May 1, 1999; 20(5): 879 - 883. [Abstract] [Full Text] [PDF]

				H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide Carcinogenesis, February 1, 1999; 20(2): 229 - 236. [Abstract] [Full Text] [PDF]

				Y. Zheng, P. M. Kramer, R. A. Lubet, V. E. Steele, G. J. Kelloff, and M. A. Pereira Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci Carcinogenesis, February 1, 1999; 20(2): 255 - 260. [Abstract] [Full Text] [PDF]

				C. Brinckerhoff, J. Coffey, and A. Sullivan Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid Science, August 19, 1983; 221(4612): 756 - 758. [Abstract] [PDF]